We Give Shareholders a Voice

Eagle Pharmaceuticals, Inc. Information Request Form

Levi & Korsinsky announces the filing of a class action lawsuit in the USDC for the District of New Jersey on behalf of shareholders of Eagle Pharmaceuticals Inc. (“Eagle Pharmaceuticals” or the “Company”) (NASDAQ: EGRX) who purchased shares between February 23, 2016 and March 18, 2016.

The lawsuit alleges that throughout the Class Period, the Company made material misrepresentations about the U.S. Food and Drug Administration’s approval process for its new drug, KANGIO™. During a February 25, 2016 earnings call, Eagle Pharmaceuticals’ CEO stated that the Company seemed “to be on track for a March 19 approval” of its anticoagulant drug KANGIO™. However, on March 18, 2016, Eagle Pharmaceuticals announced that it had received a Complete Response Letter from the FDA stating that the FDA “cannot approve the application in its present form and requested additional information” regarding the substances used in KANGIO™.

If you suffered a loss in Eagle Pharmaceuticals you have until August 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

To receive more information, please fill out the form.

Request More Information

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

This letter confirms that you have retained Levi & Korsinsky, LLP to represent you as a named plaintiff in a shareholder action involving Eagle Pharmaceuticals, Inc.

We agree to advance all expenses in the litigation, which means that you are not liable to pay any of the expenses of the lawsuit, whether attorneys' fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys' fees or costs. Should we obtain a favorable result, we may ask the court to award us compensation to be paid by the defendants or as a portion of any class benefit, but, again, we will never ask you to directly pay any of the costs of this litigation.

As the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. During the course of this litigation, we may employ and/or work with other law firms to prosecute your case.

We look forward to representing you and other Eagle Pharmaceuticals, Inc. shareholders.


Levi & Korsinsky,LLP

Joseph Levi

AGREED: Sign Name Clear